MiNK Therapeutics, Inc.
NASDAQ:INKTBiotechnology
-$0.35 today
- Market cap
- $52.17M
- Beta
- 0.47
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.60
Volume 0.01M
Average 0.05M
Big Five Numbers
MiNK Therapeutics, Inc. growth analysis
Start with the long-run numbers that show whether INKT compounds: return on capital and growth in sales, earnings, equity, and free cash flow.
Big Five Numbers
CAGR by period · ROIC shows average
| Metric | 10yr | 5yr | 3yr | 1yr |
|---|---|---|---|---|
EPS | Not available | Not available | Not available | Not available |
Revenue | Not available | Not available | Not available | Not available |
Equity | Not available | Not available | Not available | Not available |
Cash | Not available | Not available | -12.0% | +191.9% |
ROIC | Not available | 113.7% | 332.9% | -195.5% |
Analysis
In the latest year, Cash was strongest at +191.9%, while ROIC was weakest at -195.5%. The three-year average ROIC was 332.9%, a measure of how efficiently the company earned that growth.
Growth analysis
Is growth accelerating or fading?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Revenue segments
Where does the growth come from?
Break revenue down by product and geography to see which parts of the business drive the trend.
Revenue by segment
Where INKT earns its revenue, as reported in company filings
This company does not report revenue segments.
Free cash flow
Does growth turn into cash?
Check whether reported growth converts into free cash flow after capital spending.
Free Cash Flow
Net Income to FCF bridge
FY2025
Analysis
FY2025 free cash flow is -$5.9M. FCF conversion is 47.4% of net income. Operating cash flow was -$5.9M, with capex of $0. The largest bridge item is Working Capital at $3.3M.
Price targets
What do analysts expect from the price?
Compare the current price with the low, average, and high analyst targets.
Wall Street price targets
1-year price history with analyst consensus target
Unlock analyst target range
Sign in free to see low, average, high targets and implied upside for INKT.
Analyst ratings
How do analysts rate the stock?
Review the buy, hold, and sell split and recent upgrades and downgrades.
Analyst ratings
Buy, hold, and sell recommendations and recent rating changes
No analyst ratings available.
Competitor growth
How does MiNK Therapeutics, Inc. grow against peers?
Compare historical and forecast growth with similar companies.
Competitor Growth
Peer CAGR comparison & forward estimates
| Company | Market Cap | 10yr | 5yr | 3yr | Fwd |
|---|---|---|---|---|---|
Spruce Biosciences, Inc. SPRB | $133.79M | — | — | — | —3 analysts |
Outlook Therapeutics, Inc. OTLK | $106.24M | -12.2% | — | — | +233.4% (5yr)1 analysts |
NRx Pharmaceuticals, Inc. NRXP | $103.04M | — | — | — | +278.2% (5yr)1 analysts |
Equillium, Inc. EQ | $95.75M | — | — | — | —0 analysts |
vTv Therapeutics Inc. VTVT | $83.15M | — | — | — | —3 analysts |
Werewolf Therapeutics, Inc. HOWL | $49.09M | — | — | — | —1 analysts |
OS Therapies Incorporated OSTX | $46.81M | — | — | — | —1 analysts |
Gain Therapeutics, Inc. GANX | $43.93M | — | — | — | —1 analysts |
Questions
Growth questions
Common questions about INKT's growth, answered from reported and forecast figures.
Continue the stock analysis
Jump to another research area for this company.